Literature DB >> 26630444

A Methylene Group on C-2 of 24,24-Difluoro-19-nor-1α,25-dihydroxyvitamin D3 Markedly Increases Bone Calcium Mobilization in Vivo.

Agnieszka Flores1, Ilaria Massarelli2, James B Thoden1, Lori A Plum1, Hector F DeLuca1.   

Abstract

Four side chain fluorinated analogues of 1α,25-dihydroxy-19-norvitamin D have been prepared in convergent syntheses using the Wittig-Horner reaction as a key step. Structures and absolute configurations of analogues 3 and 5 were confirmed by X-ray crystallography. All analogues showed high potency in HL-60 cell differentiation and vitamin D-24-hydroxylase (24-OHase) transcription as compared to 1α,25-dihydroxyvitamin D3 (1). Most important is that all of the 20S-configured derivatives (4 and 6) had high bone mobilizing activity in vivo. However, in the 20R series, a 2-methylene group was required for high bone mobilizing activity. A change in positioning of the 20R molecule in the vitamin D receptor when the 2-methylene group is present may provide new insight into the molecular basis of bone calcium mobilization induced by vitamin D.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26630444      PMCID: PMC4698824          DOI: 10.1021/acs.jmedchem.5b01564

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Low-calcemic vitamin D analogs (deltanoids) for human cancer prevention.

Authors:  Gary H Posner
Journal:  J Nutr       Date:  2002-12       Impact factor: 4.798

2.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

3.  Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, and preliminary biological evaluation.

Authors:  Sara Peleg; Kimberly S Petersen; Byung Chul Suh; Patrick Dolan; Elin S Agoston; Thomas W Kensler; Gary H Posner
Journal:  J Med Chem       Date:  2006-12-14       Impact factor: 7.446

Review 4.  Evidence that 1,25-dihydroxyvitamin D3 is the physiologically active metabolite of vitamin D3.

Authors:  R Brommage; H F DeLuca
Journal:  Endocr Rev       Date:  1985       Impact factor: 19.871

5.  Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis.

Authors:  T W Kensler; P M Dolan; S J Gange; J K Lee; Q Wang; G H Posner
Journal:  Carcinogenesis       Date:  2000-07       Impact factor: 4.944

Review 6.  Overview of general physiologic features and functions of vitamin D.

Authors:  Hector F DeLuca
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

7.  A 20S combined with a 22R configuration markedly increases both in vivo and in vitro biological activity of 1α,25-dihydroxy-22-methyl-2-methylene-19-norvitamin D3.

Authors:  Agnieszka Flores; Rafal R Sicinski; Pawel Grzywacz; James B Thoden; Lori A Plum; Margaret Clagett-Dame; Hector F DeLuca
Journal:  J Med Chem       Date:  2012-04-22       Impact factor: 7.446

8.  Highly antiproliferative, low-calcemic, side-chain ketone analogs of the hormone 1alpha,25-dihydroxyvitamin D3.

Authors:  Gary H Posner; Hyung Jin Kim; Mehmet Kahraman; Heung Bae Jeon; Byung Chul Suh; Hongbin Li; Patrick Dolan; Thomas W Kensler
Journal:  Bioorg Med Chem       Date:  2005-10-01       Impact factor: 3.641

9.  Stabilization of the vitamin D receptor in rat osteosarcoma cells through the action of 1,25-dihydroxyvitamin D3.

Authors:  N C Arbour; J M Prahl; H F DeLuca
Journal:  Mol Endocrinol       Date:  1993-10

10.  Synthesis and biological properties of 2-methylene-19-nor-25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones--weak agonists.

Authors:  Grazia Chiellini; Pawel Grzywacz; Lori A Plum; Rafal Barycki; Margaret Clagett-Dame; Hector F DeLuca
Journal:  Bioorg Med Chem       Date:  2008-08-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.